My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Cilazapril Monohydrate (Ro 31-2848)
    Cilazapril Monohydrate (Ro 31-2848)

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V1794
    CAS #: 92077-78-6 Purity ≥98%

    Description: Cilazapril Monohydrate (Ro 31-2848) is a potent angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and congestive heart failure. Cilazapril is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat. It is known that the diacid form of Cilazapril is more potent that enalapril at inhibiting ACE.

    References: J Pharmacol Sci. 2004 Jan;94(1):67-72; Life Sci. 1999;64(3):PL27-39.

    Related CAS #: 92077-78-6 (hydrate); 88768-40-5 (free)                     

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)435.51 
    FormulaC22H31N3O5.H2O 
    CAS No.92077-78-6 
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 87 mg/mL (199.8 mM) 
    Water: <1 mg/mL
    Ethanol: 87 mg/mL (199.8 mM) 
    SMILESO=C([[email protected]@H]1CCCN2N1C([[email protected]@H](N[[email protected]](C(OCC)=O)CCC3=CC=CC=C3)CCC2)=O)O.O
    SynonymsRo 31-2848 monohydrate; Ro31-2848 monohydrate; Ro-31-2848 monohydrate; Ro-31 2848 monohydrate; 


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    In vitro activity: Cilazapril is one of the angiotensin-converting enzyme inhibitors (ACE inhibitors) used for hypertension. 

    In VivoCilazapril (1 mg/kg, daily) tends to decrease and the higher dose (10 mg/kg, daily) significantly decreases systolic blood pressure (SBP) in subtotal nephrectomized rats. Cilazapril attenuates the further development of protein uria in a dose-dependent manner in subtotal nephrectomized rats. Cilazapril attenuates the increase in plasma fibrinogen concentration and serum albumin concentration in a dose-dependent manner. Cilazapril reduces serum MCP-1 concentration in the nephrectomized rats. Cilazapril decreases hepatic fibrinogen synthesis through the alleviation of the local inflammatory process and the improvement of hypoalbuminemia. Cilazapril normalizes systolic arterial pressure to 121 mm Hg (SD) in the treated SHR-SP rats. Cilazapril decreases systolic arterial pressure to a nearly normal level and prevents hypertensive retinal vascular changes, probably by improving endothelial function. Cilazapril results in a marked decrease in the Kd of the renal arginine vasopressin (AVP) receptor and an increase in the plasma AVP level in the spontaneously hypertensive rat. Cilazapril exerts a rapid, complete, and persistent antihypertensive effect in the spontaneously hypertensive rats (SHR) in vivo but has no effect on SAP in the normotensive Sprague-Dawley rat. Cilazapril treatment depresses heart performance (28-35%) in SHR but has no effect in the Sprague-Dawley rats. Cilazapril decreases blood pressure to control values and reduces HW:BW in hyperthyroid rats.
    Animal modelRats
    Formulation & Dosage1 mg/kg
    References

    J Pharmacol Sci. 2004 Jan;94(1):67-72; Life Sci. 1999;64(3):PL27-39. 


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?